LAUSR

BACKGROUND Silencing of several genes are critical for cancer therapy. These genes may be apoptotic gene, cell proliferation gene, DNA synthesis gene etc. Ribonucleotide Reductase (RR) two subunit RRM1 and RRM2 are critical for DNA synthesis. Hence targeting the blockage of DNA synthesis at tumour site can be a smart mode of cancer therapy. Specific targeting of blockage of RRM2 has been done effectively by SiRNA. The drawback of siRNA delivery in the body is pool uptake by all kinds of cell, questionable stability under physiological condition, non-target effect and ability to trigger immune response. These obstacles may be overcome by target delivery of siRNA at tumour site. This review presents a holistic overview about role of RRM2 in controlling cancer progression. The nanoparticles are more effective due to its specific characters like cell membrane penetration capacity, less toxicity etc. RRM2 have been found to be elevated in different type of cancer and has been identified as the prognostic and predictive marker of the disease. Reductase. RRM1 and RRM2 regulate the protein and gene expression of E2F which is critical for protein expression and progression of cell cycle and cancer. Knockdown of RRM2 leads to apoptosis via Bcl2 in cancer. Both Bcl2 and E2F is critical in progression of cancer, hence a gene that can affect both in regulating DNA replication is essential for cancer therapy. AIM The aim of the review is to identify critical and related gene whose silencing may inhibit cancer progression. CONCLUSION In this review, we illuminate the critical link between RRM-E2F, RRM-Bcl2, RRM-HDAC for the therapy of cancer. Altogether, this review presents an overview on all type of SiRNA targeted for cancer therapy with especial emphasis on RRM2 for controlling tumour progression.